• objective response rate [ Time Frame: 18months ]
  Complete response (CR)+Partial response (PR) according to RECIST 1.1
• overall survival (OS) [ Time Frame: Approximately 36 months ]
  Overall survival was defined as the time from randomization to death from any cause
• adverse event (AE) [ Time Frame: Approximately 36 months ]
  adverse event according to NCI-CTCAE (5.0)

• Drug: Endostar
  Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
  Other Name: Recombinant human endostatin injection
• Drug: Cisplatin
  Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
• Drug: Docetaxel
  Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
• Radiation: Intensity Modulated Radiation Therapy (IMRT)
  IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions

• Experimental: Experimental group
  Drug: Endostar Drug: Cisplatin Drug: Docetaxel Radiation
  Interventions:

  • Drug: Endostar
  • Drug: Cisplatin
  • Drug: Docetaxel
  • Radiation: Intensity Modulated Radiation Therapy (IMRT)
• Control group
  Drug: Cisplatin Drug: Docetaxel Radiation
  Interventions:

  • Drug: Cisplatin
  • Drug: Docetaxel
  • Radiation: Intensity Modulated Radiation Therapy (IMRT)

Inclusion Criteria:

1. Pathologically or clinically confirmed locally recurrent nasopharyngeal carcinoma;
2. No chemotherapy, immunotherapy, radiotherapy treatment history.
3. No evidence of distant metastasis
4. Eastern Cooperative Oncology Group performance score 0-1
5. Normal bone marrow function: white blood cell count > 3.5 × 109 / L, hemoglobin > 90 g / L and platelet count > 100 × 109 / L.
6. Normal liver function: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) <1.5 times the upper limit of normal (ULN), and alkaline phosphatase (ALP) < 2.5 × ULN
7. Normal renal function: creatinine clearance > 60 ml/min.
8. The patient must be informed of the basic content of the study and sign an informed consent form.

Exclusion Criteria:

1. The pathological type is keratinized squamous cell carcinoma or basal squamous cell carcinoma.
2. Treatment is palliative.
3. A history of malignant tumors, except for well-treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ.
4. Women during pregnancy or lactation (pregnancy tests should be considered for women of childbearing age; effective contraception should be emphasized during treatment).
5. Previous radiation therapy (except for non-melanoma skin cancer with a previous lesion outside the target area of radiotherapy).
6. Primary and cervical metastatic lesions have received chemotherapy or surgery (except for diagnostic treatment).
7. Having other serious illnesses may result in greater risk or affect the compliance of the trial. For example: kidney disease, chronic hepatitis, control of unsatisfactory diabetes (fasting blood glucose > 1.5 × ULN), and mental illness.
8. A history of severe heart disease, including: cardiac function ≥ standard II, unstable angina, myocardial infarction, arrhythmia - antiarrhythmic drug therapy (except beta-blockers or digoxin), Uncontrollable hypertension.
9. According to the investigator's judgment, there are people with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study.
10. Patients with a major bleeding tendency in the primary nasopharyngeal tumors.